The clinical stage biopharmaceutical Pulmatrix, recently announced the completion of a pilot study to access the pharmacokinetics of PUR0200 for maintenance treatment of bronchospasms in patients with chronic obstructive pulmonary disease (COPD). The testing of PUR0200, a dry powdered generic of a once-daily, long-acting muscarinic antagonist, was done using healthy volunteers. In Europe,…
GlaxoSmithKline (GSK) recently presented new data from a pre-specified analysis of the SUMMIT clinical trial, showing that once daily treatment with Breo Ellipta (fluticasone furoate/vilanterol) reduced exacerbations in chronic obstructive pulmonary disease (COPD) patients compared to placebo. The presentation was one of two given at the American Thoracic Society (ATS) 2016 International…
AstraZeneca is presenting a broad selection of its novel respiratory disease medicines through more than 60 abstracts and scientific presentations at the American Thoracic Society (ATS) 2016 International Conference through May 18 in San Francisco, Calif. Presentations highlight combinations, respiratory biologics, and scientific research projects that target new pathways…
Sunovion Pharmaceuticals, Inc., will present new clinical and health outcomes data for its Brovana (arformoterol tartrate) Inhalation Solution at the 2016 American Thoracic Society International Conference (ATS 2016), taking place May 13–18 in San Francisco, California. At the ATS meeting, Sunovion will present post-hoc analyses of clinical data generated from its…
BioScale, Inc. has changed its name to ProterixBio, Inc. to mirror the company’s new strategic path centered on high value clinical applications including disease management services and diagnostics products, according to a May 3 news release. ProterixBio is developing pioneering products to transform chronic disease management. The company will…
Sunovion Pharmaceuticals, Inc., recently reported positive data on its Phase 3 clinical development program for SUN-101 (glycopyrrolate) for the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD). SUN-101 is dispensed using PARI’s investigational and proprietary nebulizer system, called eFlow. Two 12-week, randomized, double-blind, placebo-controlled and parallel-group, Phase 3 efficacy and safety trials (GOLDEN-3 and…
Aptar Pharma, a global provider of aerosols for healthcare and pharma products, unveiled its latest innovation — the eDose Counter for metered dose inhalers (MDIs) — at the Respiratory Drug Delivery (RDD) Scientific Conference April 17-21 in Phoenix, Arizona. The eDose Counters are engineered to improve treatment adherence in patients…
Propeller Health and AMC Health are partnering to assist patients with chronic obstructive pulmonary disease (COPD) and asthma manage their disease more efficiently and reduce symptoms, as well as hospital visits. The multi-year partnership was signed in January and will kick off this month with the launch of two…
The U.S. Food and Drug Administration (FDA) recently approved a Supplemental New Drug Application (sNDA) for Boehringer Ingelheim Pharmaceuticals Inc.‘s Stiolto Respimat, adding data to the product’s labeling to reflect its demonstrated capacity to improve health-related quality of life in people with chronic obstructive pulmonary disease (COPD). Data came from Phase 3 clinical trials, OTEMTO…
Boehringer Ingelheim Pharmaceuticals and Propeller Health are partnering to use digital health tools and services to help patients with asthma and chronic obstructive pulmonary disease (COPD) to better cope with their condition. Under the terms of the commercial agreement, people with asthma and COPD who are currently taking a Boehringer Ingelheim…
Get regular updates to your inbox.